Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 185,700 shares, a decline of 19.2% from the January 15th total of 229,900 shares. Based on an average daily volume of 414,100 shares, the days-to-cover ratio is presently 0.4 days.
Shares of OTCMKTS SGIOY traded down $0.08 during trading on Friday, reaching $7.06. The company had a trading volume of 122,169 shares, compared to its average volume of 202,678. Shionogi & Co., Ltd. has a twelve month low of $6.22 and a twelve month high of $9.11. The stock has a market capitalization of $12.01 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 2.36 and a beta of 0.23. The stock has a 50-day moving average price of $7.08 and a two-hundred day moving average price of $8.31.
Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $0.16 EPS for the quarter. Shionogi & Co., Ltd. had a return on equity of 11.95% and a net margin of 35.53%. On average, sell-side analysts predict that Shionogi & Co., Ltd. will post 0.66 EPS for the current year.
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Shionogi & Co., Ltd., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. wasn't on the list.
While Shionogi & Co., Ltd. currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.